Cannabinoid Receptor Agonist Lenabasum Promising for Dermatomyositis - Dermatology Advisor

The safety and efficacy of lenabasum use in patients with refractory cutaneous dermatomyositis is assessed.

Lenabasum, a cannabinoid receptor type 2 (CB2) agonist which decreases inflammation, was well tolerated and associated with improved efficacy against dermatomyositis, according to findings from a pha… [+3044 chars]

full article...